Chemotherapy for Mesothelioma

Chemotherapy for mesothelioma uses cytotoxic drugs to kill cancer cells or inhibit their growth. It is a cornerstone of mesothelioma treatment, used as first-line systemic therapy for unresectable disease, as neoadjuvant therapy before surgery, as adjuvant therapy after surgery, and as heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma.¹

The standard first-line chemotherapy regimen for mesothelioma is the combination of pemetrexed (Alimta) plus cisplatin, which received FDA approval in 2004 based on a landmark phase III trial demonstrating a significant survival improvement over cisplatin alone. For patients who cannot tolerate cisplatin, carboplatin is substituted with comparable efficacy and a more favorable toxicity profile.²

The introduction of immunotherapy (nivolumab plus ipilimumab) as a first-line alternative in 2020 has expanded the treatment landscape for mesothelioma. The choice between chemotherapy and immunotherapy as initial treatment depends on the tumor's histological subtype, with immunotherapy showing particular benefit in non-epithelioid (sarcomatoid and biphasic) mesothelioma, while chemotherapy remains highly effective for epithelioid disease.³

Chemotherapy can be administered intravenously (systemically), directly into the pleural space (intrapleural), or heated and circulated through the abdominal cavity (HIPEC). The delivery method depends on the type of mesothelioma and the treatment intent (curative vs. palliative).¹

First-line systemic chemotherapy

The standard first-line chemotherapy regimen for malignant pleural mesothelioma is:²

• Pemetrexed 500 mg/m² IV + cisplatin 75 mg/m² IV — administered on day 1 of a 21-day cycle, for 4–6 cycles. This regimen demonstrated a median overall survival of 12.1 months versus 9.3 months for cisplatin alone in the pivotal Vogelzang trial (2003), with an objective response rate of 41.3% versus 16.7%.²
• Pemetrexed + carboplatin — Carboplatin (AUC 5) is substituted for cisplatin in patients with renal impairment, hearing loss, neuropathy, or poor performance status. Efficacy is comparable, with lower rates of nephrotoxicity, ototoxicity, and emesis.¹

Required supplementation: All patients receiving pemetrexed must take folic acid (400–1000 μg daily, starting 7 days before first dose) and vitamin B12 (1000 μg IM, at least 7 days before first dose, then every 9 weeks). These supplements reduce the risk of severe myelosuppression and mucositis without affecting anti-tumor efficacy.²

Bevacizumab addition

The MAPS trial (2016) demonstrated that adding bevacizumab (Avastin, 15 mg/kg IV) to pemetrexed/cisplatin improved median overall survival from 16.1 to 18.8 months. Bevacizumab is an anti-VEGF monoclonal antibody that inhibits tumor blood vessel formation. This triplet regimen is an option for patients who can tolerate bevacizumab (no recent surgery, no uncontrolled hypertension, no history of hemoptysis).⁴

Second-line chemotherapy

There is no FDA-approved second-line chemotherapy for mesothelioma. Options after first-line progression include:¹

• Pemetrexed re-challenge — If the initial response to pemetrexed lasted ≥3 months, re-treatment with pemetrexed-based chemotherapy is reasonable and produces response rates of 15–25%.
• Gemcitabine — Single-agent gemcitabine or gemcitabine-based combinations have modest activity in mesothelioma.
• Vinorelbine — A vinca alkaloid with single-agent activity in mesothelioma, producing response rates of 10–20%.¹
• Immunotherapy — Nivolumab plus ipilimumab or single-agent nivolumab/pembrolizumab are commonly used in the second-line setting.³

Neoadjuvant and adjuvant chemotherapy

Chemotherapy is used before surgery (neoadjuvant) to reduce tumor bulk and improve resectability, or after surgery (adjuvant) to eliminate residual microscopic disease. Pemetrexed/cisplatin is the standard perioperative regimen, typically given for 2–4 cycles before surgery and an additional 2–4 cycles after surgery.⁵

HIPEC (heated intraperitoneal chemotherapy)

For peritoneal mesothelioma, chemotherapy is delivered directly into the abdominal cavity at elevated temperatures (41–43°C) during cytoreductive surgery. Commonly used agents include cisplatin, mitomycin C, and doxorubicin. The heat enhances drug penetration into residual tumor deposits, and the direct peritoneal delivery achieves drug concentrations 20–100 times higher than those achievable with IV chemotherapy while minimizing systemic toxicity.⁶

Chemotherapy has a meaningful but modest impact on mesothelioma survival. The key survival benchmarks are:²

• Pemetrexed/cisplatin — Median overall survival: 12.1 months (vs. 9.3 months for cisplatin alone)²
• Pemetrexed/cisplatin + bevacizumab — Median overall survival: 18.8 months⁴
• Pemetrexed/cisplatin as part of multimodal therapy — Median overall survival: 16–29 months, depending on surgical approach and patient selection⁵
• Peritoneal mesothelioma with CRS/HIPEC — Median overall survival: 50–60+ months with complete cytoreduction⁶

Factors that predict better response to chemotherapy include epithelioid histology, good performance status (ECOG 0–1), early-stage disease, and younger age. Sarcomatoid mesothelioma has the poorest response to chemotherapy, which is one reason immunotherapy is preferred for non-epithelioid disease.¹

Managing the side effects of chemotherapy is a critical component of mesothelioma treatment. Patients and caregivers should be prepared for the following challenges:

Common side effects of pemetrexed/cisplatin:

• Nausea and vomiting — Cisplatin is highly emetogenic. Modern anti-nausea regimens (5-HT3 antagonists, NK1 antagonists, dexamethasone) effectively prevent vomiting in most patients.
• Fatigue — The most common side effect. Fatigue typically peaks 3–5 days after each treatment cycle and gradually improves before the next cycle. Light exercise and energy conservation techniques help manage fatigue.
• Myelosuppression — Reduced blood cell counts (anemia, neutropenia, thrombocytopenia). Folic acid and B12 supplementation significantly reduces this risk with pemetrexed. Blood counts are monitored before each cycle.
• Nephrotoxicity — Cisplatin can damage the kidneys. Aggressive IV hydration before and after cisplatin infusion protects kidney function. Serum creatinine is monitored before each cycle. Carboplatin is used instead of cisplatin for patients with kidney concerns.²
• Peripheral neuropathy — Tingling, numbness, or pain in the hands and feet from cisplatin-induced nerve damage. This can be dose-limiting and is sometimes irreversible.
• Hearing loss (ototoxicity) — Cisplatin can cause high-frequency hearing loss. Audiometry monitoring is recommended.
• Loss of appetite — Nutritional counseling and small, frequent meals help maintain caloric intake during treatment.

Practical guidance:

• Take folic acid and vitamin B12 supplements exactly as prescribed — they significantly reduce toxicity without affecting treatment efficacy
• Stay well-hydrated, especially in the days surrounding cisplatin treatments
• Report new or worsening symptoms promptly — early intervention for side effects prevents complications
• Discuss fertility preservation before starting treatment if relevant
• Maintain regular follow-up appointments for blood work and imaging assessments